Vol 8, No 5 (October 09, 2019): Chinese Clinical Oncology (Molecular Markers in Colorectal Cancer)

Original Article

The association of KRAS mutation with primary tumor location and survival in patients undergoing resection of colorectal cancers and synchronous liver metastases
Niccolo Allievi, Paolo Goffredo, Alan F. Utria, Michele Pisano, Elia Poiasina, Alessandro Lucianetti, Paige Zhou, Imran Hassan

Review Article

Japanese experience with hepatic resection of KRAS-mutated colorectal liver metastases
Junichi Shindoh
Limitations of molecular biomarkers in patients with resectable colorectal liver metastases
Kristoffer W. Brudvik, Junichi Shindoh
Current and evolving biomarkers for precision oncology in the management of metastatic colorectal cancer
Jason Timothy Henry, Benny Johnson
Interactions of multiple gene alterations in colorectal liver metastases
Yoshikuni Kawaguchi, Jenilette D. Velasco, Elsa M. Arvide, Steven H. Wei, Jean-Nicolas Vauthey
Tailoring ablation strategies for colorectal liver metastases based upon rat sarcoma viral oncogene mutation status
Marco Calandri, Bruno C. Odisio
The impact of somatic SMAD4 mutations in colorectal liver metastases
Dimitrios Xourafas, Takashi Mizuno, Jordan M. Cloyd
Review: KRAS mutations are influential in driving hepatic metastases and predicting outcome in colorectal cancer
Colin W. Steele, Thomas Whittle, J. Joshua Smith
The state of hepatic artery infusion chemotherapy in the management of metastatic colorectal cancer to the liver
Marcia Leung, Sepideh Gholami
RAS mutation: site of disease and recurrence pattern in colorectal cancer
Pierre E. Bonnot, Guillaume Passot

Disclosure:

The focused issue “Molecular Markers in Colorectal Cancer” was commissioned by the Editorial office, Chinese Clinical Oncology without any sponsorship or funding. Yun Shin Chun and Michael D’Angelica served as the unpaid Guest Editors for the focused issue.